TNFRSF1B and cancer: The results from the first clinical trial recently launched to evaluate an anti-TNFR2 antagonist (BI-1808) from BioInvent International AB (Lund, Sweden) in cancer patients (NCT04752826) should help to clarify the best way to target TNFR2 in humans.